India's CDSCO Panel Recommends Waiving Phase III Trials for Generic Lenacapavir
GILD sits 37% above its 52-week low of $108.46 on elevated volume (2.4× avg).
Summary
India's CDSCO subject expert committee recommended waiving local Phase III trials and bioequivalence studies for generic lenacapavir, citing unmet medical need. This clears a major hurdle for Indian manufacturers like Emcure, Dr Reddy's, and Hetero to launch affordable versions of Gilead's long-acting HIV drug. Emcure has already filed its injectable with DCGI and expects approval by fiscal year-end. The move accelerates generic rollout in licensed low- and middle-income markets, expected from 2027, with annual treatment cost around $40 versus $28,000-$42,000 in developed markets. Gilead's voluntary licensing agreements from 2024 cover 120 countries, including India, so this development expands access without direct revenue impact to Gilead. The waiver applies to prevention indication; treatment indication for multidrug-resistant HIV still lacks a similar waiver, leaving an access gap.
At the time of this announcement, GILD was trading at $149.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $186.1B. The 52-week trading range was $108.46 to $157.29. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Moneycontrol.